Hepatitis C-A clinical review.
With an estimated prevalence of about 170 million people worldwide, chronic hepatitis C is an important cause of chronic liver disease associated with a substantial risk of cirrhosis and hepatocellular carcinoma. The recent past has borne witness to remarkable advancements in the treatment of chronic hepatitis C with the development of novel, effective, and well tolerated medications that have resulted in paradigm shifts in treatment approaches and may potentially affect the natural history of the disease. We provide a clinical review of current concepts and future developments in the management of chronic hepatitis C to aid in the understanding and individualization of chronic hepatitis C treatment. J. Med. Virol. 88:1844-1855, 2016. © 2016 Wiley Periodicals, Inc.
Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Texas Health Science Center at Houston, Houston, Texas.
Lan S
LS
Wang
Division of Digestive Diseases, Department of Medicine, Mount Sinai Beth Israel Medical Center, New York, New York.
Lionel S
LS
D'Souza
Division of Digestive Diseases, Department of Medicine, Mount Sinai Beth Israel Medical Center, New York, New York.
Ira M
IM
Jacobson
D000998:Antiviral Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000821:virology; D019468:Disease Management; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy; D008113:Liver Neoplasms / Q000821:virology; D015995:Prevalence; D011640:Public Policy
D000998:Antiviral Agents
anti-hepatitis C virus directly acting antivirals; hepatitis C virus; public policy